Stem cell microcapsule-entrapped tissue adhesive as well as preparation method and application thereof

By using tissue adhesives that encapsulate stem cell microcapsules and employing droplet microfluidics and bioadhesives to form a stable three-dimensional network structure, the problems of low survival rate and short retention time of stem cells in the nasal mucosa environment have been solved, thus achieving effective treatment for chronic sinusitis.

CN121401185APending Publication Date: 2026-01-27DALIAN UNIV OF TECH +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511464633.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-10-14
Publication Date
2026-01-27

AI Technical Summary

Technical Problem

Existing technologies are insufficient to effectively repair the nasal mucosal barrier, traditional drug treatments have difficulty penetrating the sinus anatomy, have short durations of efficacy, and high recurrence rates after surgery. Stem cell therapy has low survival rates and short retention times in the local mucosal environment, resulting in unstable treatment outcomes for chronic sinusitis.

Method used

By using a tissue adhesive that encapsulates stem cell microcapsules, uniformly sized microcapsules are prepared using droplet microfluidic technology. These microcapsules, combined with a bio-adhesive, form a stable three-dimensional network structure, enabling local retention and continuous release of stem cells, repairing nasal mucosal damage, and inhibiting inflammatory responses.

Benefits of technology

It significantly improved the retention rate and therapeutic durability of stem cells in the nasal mucosa, continuously released cytokines and exosomes, promoted epithelial repair and functional recovery, reduced postoperative recurrence rate, and improved the inflammatory microenvironment of chronic sinusitis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121401185A_ABST
    Figure CN121401185A_ABST
Patent Text Reader

Abstract

The invention discloses a stem cell microcapsule-entrapped tissue adhesive, a preparation method and application, the tissue adhesive is composed of stem cell microcapsule-entrapped hydrogel and a biological adhesive, and live stem cells are entrapped in the tissue adhesive; the stem cells are selected from at least one of umbilical cord mesenchymal stem cells, bone marrow mesenchymal stem cells, adipose-derived stem cells, embryonic stem cells and induced pluripotent stem cells; the biological adhesive is formed by compounding a hydrophilic polymer and a block polymer, wherein the mass ratio of the hydrophilic polymer to the block polymer is (1: 5)-(5: 1); the transmittance of the tissue adhesive is 60-100%, the tissue adhesive strength is 20-200 kPa, and the volume swelling ratio is smaller than or equal to 50%. According to the scheme, the stem cell entrapped microcapsule and the biological adhesive are mixed to prepare the tissue adhesive, and the adhesive can be used as bio-ink to be assembled into a bionic scaffold through 3D printing or directly injected to an injured part, so that the tissue adhesive has a wide application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology, specifically relating to a tissue adhesive for encapsulating stem cell microcapsules, its preparation method, and its application. Background Technology

[0002] Chronic sinusitis is a common and difficult-to-treat chronic inflammatory disease that primarily affects the nasal cavity and paranasal sinus mucosa. It is characterized by symptoms such as nasal congestion, rhinorrhea, decreased sense of smell, and facial pain lasting for more than 12 weeks. Epidemiological studies indicate that the incidence of chronic sinusitis is approximately 5%–15% of the global population, placing a heavy burden on patients' quality of life, social productivity, and the healthcare system. Based on clinical and pathological characteristics, chronic sinusitis can be divided into two types: with and without nasal polyps. Its pathogenesis is complex, involving multiple factors such as mucosal barrier dysfunction, local immune imbalance, bacterial biofilm infection, and abnormal tissue remodeling. The disruption of the nasal mucosal epithelium is considered a key factor in the occurrence and progression of chronic sinusitis. Normal nasal epithelium maintains barrier integrity through tight junction proteins and secretes antimicrobial peptides and mucus to resist external stimuli. However, in a chronic inflammatory state, the mucosal epithelium is damaged, and the expression of cell junction proteins decreases, making it easier for pathogenic microorganisms, allergens, and pollutants to penetrate into the underlying tissues, further inducing an inflammatory cascade. Meanwhile, the overactivated immune response manifests as eosinophil infiltration, increased Th2 cells, and abnormal expression of various inflammatory factors (such as IL-4, IL-5, IL-13, and IL-33), leading to tissue edema, glandular hyperplasia, and fibrosis, resulting in irreversible mucosal remodeling. Current treatments for chronic sinusitis mainly include drug therapy (glucocorticoids, antibiotics, and anti-leukotriene drugs) and functional endoscopic sinus surgery. However, traditional drug therapy struggles to penetrate the complex anatomical structure of the sinuses, has a short duration of efficacy, and long-term use of hormones has side effects. While surgery can remove lesions and improve drainage, the recurrence rate is high, especially in patients with nasal polyps, where it can exceed 40%. How to effectively repair the nasal mucosal barrier, inhibit chronic inflammation, and promote tissue regeneration in postoperative or non-surgical treatments has become a key focus and challenge in current clinical research. Stem cell therapy offers a new approach to tissue repair in chronic sinusitis. Mesenchymal stem cells possess multiple characteristics, including low immunogenicity, immunomodulatory capacity, and the ability to promote tissue regeneration. Studies have shown that MSCs secrete various cytokines and exosomes through the paracrine pathway, which can inhibit inflammatory responses, promote epithelial cell repair and angiogenesis, and regulate the transformation of immune cells to anti-inflammatory phenotypes, thereby improving the nasal mucosal microenvironment. Animal experiments and preliminary clinical studies have shown that local application of MSCs can significantly reduce nasal mucosal inflammation, decrease eosinophil infiltration, and promote epithelial remodeling. However, stem cell therapy still faces key challenges: low survival rate and short retention time in the local mucosal environment, and limitations imposed by nasal mucus flow and immune clearance, leading to unstable treatment effects. To overcome this challenge, stem cell microcapsule delivery systems based on adhesive hydrogels have gradually attracted attention. Adhesive hydrogels encapsulating stem cell microcapsules possess good biocompatibility, injectability, and good adhesion to tissues, providing a three-dimensional support structure for stem cells, improving the local microenvironment, and prolonging cell survival time.In recent years, micron-scale stem cell microcapsule technology has achieved high-precision control of cell encapsulation through microfluidic droplet methods, forming uniformly sized, biodegradable microcapsule structures that effectively protect cells from mechanical and immune stress damage. Simultaneously, the porous structure of the microcapsules facilitates the exchange of nutrients and metabolites, maintaining cell viability and enhancing paracrine function. Combining stem cell-encapsulated microcapsules with tissue-adhesive bioadhesives significantly improves local retention and therapeutic durability. The tissue adhesive maintains good adhesion even in moist environments, fixing the microcapsules to the sinus mucosa surface while forming a biocompatible protective barrier to prevent dilution and erosion by inflammatory exudate, while simultaneously enabling sustained local release of stem cell secreted factors. This composite system not only possesses good mechanical strength and biodegradability but also forms a highly permeable and low-swelling-rate three-dimensional network on the tissue surface, maintaining cell viability and promoting mucosal regeneration. Therefore, local delivery systems based on tissue adhesive-encapsulated stem cell microcapsules hold promise as a novel strategy for the treatment of chronic sinusitis, combining anti-inflammatory regulation, tissue repair, and local sustained-release functions. This system can form a stable bio-adhesion layer at the lesion site, continuously release stem cell paracrine factors, improve the nasal cavity microenvironment, promote epithelial barrier reconstruction and reduce postoperative recurrence, and has significant clinical translational potential. Summary of the Invention

[0003] The present invention aims to provide a method for preparing stem cell microcapsules encapsulated in a tissue adhesive and its application in the treatment of chronic sinusitis. This invention constructs a composite system with tissue adhesion and cell sustained-release functions by combining injectable, curable biological tissue adhesive with stem cell-loaded microcapsules, for repairing nasal mucosal damage, inhibiting inflammatory responses, and promoting tissue regeneration. The invention uses natural polymer materials such as alginate, methacrylic acid-modified gelatin, and hyaluronic acid, and utilizes droplet microfluidic technology to prepare stem cell-loaded microcapsules with uniform particle size and high cell activity. These microcapsules are then dispersed in a biological adhesive composed of polyethylene glycol, polyvinyl alcohol, and poloxamer, forming a stable three-dimensional network structure through a cross-linking reaction. The resulting composite system can solidify in situ in the moist environment of the nasal cavity and firmly adhere to the nasal mucosa surface, achieving local retention and sustained release of stem cells. This system can effectively improve the local microenvironment of the nasal mucosa, inhibit inflammatory cell infiltration, promote epithelial repair and functional recovery, thereby significantly improving the therapeutic effect of chronic sinusitis. The tissue adhesive-encapsulated stem cell microcapsules of the present invention have the advantages of simple preparation, strong adhesion, good biocompatibility and long-lasting treatment, and have broad application prospects in chronic sinusitis and other chronic inflammatory diseases of the mucosa.

[0004] According to a first aspect of the present invention, a tissue adhesive for encapsulating stem cell microcapsules is provided, the tissue adhesive being composed of a stem cell microcapsule hydrogel and a biological adhesive, wherein the microcapsule contains living stem cells. The stem cells are selected from at least one of umbilical cord mesenchymal stem cells, bone marrow mesenchymal stem cells, adipose stem cells, embryonic stem cells, and induced pluripotent stem cells; The bioadhesive is composed of a hydrophilic polymer and a block polymer, wherein the mass ratio of the hydrophilic polymer to the block polymer is 1:5 to 5:1. The tissue adhesive has a transmittance of 60-100%, a tissue adhesion strength of 20-200 kPa, and a volume swelling rate of less than 50%.

[0005] Based on the above technical solution, the number of live cells in the stem cell-carrying microcapsule is 1 to 10; The microcapsules carrying stem cells have a particle size of 50-150µm and a particle size distribution dispersion coefficient of 0.01-20%.

[0006] Based on the above technical solution, the hydrophilic polymer is selected from at least one of polyethylene glycol, polyvinyl alcohol, gelatin, hyaluronic acid, alginate, and chitosan; When the hydrophilic polymer is polyethylene glycol, the molecular weight is 0.2 kDa to 6 kDa, preferably a combination of two or more of 0.2 kDa, 2 kDa, 4 kDa and 6 kDa, wherein the mass ratio of polyethylene glycol with molecular weights of 0.2 kDa, 2 kDa, 4 kDa and 6 kDa is 0~10:0~10:0~10:0~10; When the hydrophilic polymer is polyvinyl alcohol, the molecular weight is 2 kDa~75 kDa; When the hydrophilic polymer is hyaluronic acid, alginate, or chitosan, the degree of functional gene modification is ≥50%; When the hydrophilic polymer is gelatin, the degree of functional gene modification is ≥60%; The block polymer is poloxamer; The poloxamer is selected from at least two combinations of F127, F108, F88, F68, and F87, wherein the mass ratio of F127, F108, F88, F68, and F87 is 0-10:0-10:0-10:0-10:0-10.

[0007] According to a second aspect of the present invention, a method for preparing a tissue adhesive encapsulating stem cell microcapsules is provided, comprising the following steps: (1) Preparation of hydrogel prepolymer: Alginate was dissolved in culture medium, and a crosslinking initiator was added to carry out crosslinking reaction to obtain hydrogel prepolymer; (2) Stem cell culture: The stem cells are passaged and cultured until the cells grow to more than 80%. They are washed and the hydrogel prepolymer obtained in step (1) is added to obtain the stem cell microcapsule prepolymer solution. (3) Preparation of stem cell-loaded microcapsules: The stem cell-loaded microcapsule prepolymer obtained in step (2) is used to prepare microdroplets through a microfluidic chip, which initiates a gelation reaction, removes the aqueous phase, and obtains cell microcapsules.

[0008] (4) Preparation of adhesive for carrying stem cell microcapsules: Mix the cell microcapsules obtained in step (3) with the biological adhesive, add a cross-linking initiator to carry out the cross-linking reaction, and obtain the adhesive for carrying stem cell microcapsules. The bioadhesive is composed of a hydrophilic polymer and a block polymer, wherein the volume percentage of the polymer is 5% to 80%.

[0009] Based on the above technical solution, the salt in the alginate in step (1) is a metal salt, selected from at least one of calcium, barium, strontium, magnesium, iron, zinc, aluminum, copper, nickel, and gallium; In steps (1) and (4), the crosslinking initiator is a coordination reaction initiator, namely a chelate formed by one of the following ions: calcium ion, barium ion, strontium ion, magnesium ion, iron ion, zinc ion, aluminum ion, copper ion, nickel ion, and gallium ion with ethylenediaminetetraacetic acid or aminotriacetic acid. The concentration of the crosslinking initiator is 10~1000mM, based on calcium content; The volume fraction of the polymer in the bio-adhesive described in step (4) is 20% to 60%.

[0010] Based on the above technical solution, in step (1), alginate is replaced with modified polymer material; The polymer material is selected from at least one of hyaluronic acid, gelatin, chitosan, agarose, dextran, fibroin, agar, matrix gum, proteoglycan, glycoprotein, laminin, polyethylene glycol, polyethylene glycol derivatives, polyvinyl alcohol, polyethylene oxide, polyamino acids, polyacrylamide, and Pluronic. The modifier in the modified polymer material is selected from at least one of acrylate, methacrylate, allyl isocyanate, azide, and alkyne; When alginate is replaced by polymer materials, crosslinking initiators include photochemical initiators, temperature-mediated crosslinking agents, and enzymes; The photochemical initiator is selected from at least one of 2-hydroxy-4-(2-hydroxyethoxy)-2-methylphenylacetone, lithium phenyl-2,4,6-trimethylbenzoylphosphonate, azo initiator VA086, benzoin methyl ether, and eosin Y, preferably, the irradiation wavelength is 365~780nm and the irradiation time is 0.00001~600s; The temperature-mediated crosslinking agent is used at a temperature of 0~40℃; The enzyme is selected from one of superoxide dismutase, thrombin, and glutaminase.

[0011] Based on the above technical solution, in step (2), the stem cells are selected from at least one of umbilical cord mesenchymal stem cells, bone marrow mesenchymal stem cells, adipose stem cells, embryonic stem cells, and induced pluripotent stem cells. The cell concentration of the stem cell-carrying microcapsule prepolymer solution mentioned in step (2) is greater than or equal to 4*10⁻⁶. 6 per mL.

[0012] Based on the above technical solution, the microfluidic chip in step (3) is a single-channel or multi-channel microfluidic chip. The microfluidic chip has at least a two-phase liquid inlet, an emulsification channel, and an output channel. The two-phase liquid inlet includes an aqueous liquid inlet and an oil liquid inlet. The inner wall of the microchannel of the microfluidic chip is hydrophobically treated. The process of preparing microdroplets in step (3) is as follows: using a micropump or microinjector, a monodisperse water / oil / water double emulsion, i.e., microdroplets, is formed in the corresponding microchannels of the microfluidic device for the aqueous phase solution and oil phase solution composed of multiple fluids.

[0013] The flow rate of the aqueous solution is 10~500μL / hr, preferably 20~100μL / h; The flow rate of the oil phase solution is 500~3000μL / hr, preferably 800~1000μL / h; The flow rate ratio of the aqueous solution to the oil solution is 0.01 to 1, preferably 0.1 to 0.5; The aqueous solution is the prepolymer solution of the stem cell-carrying microcapsules described in step (2); The oil phase solution is a mixed solution of fluorinated surfactant and fluorinated oil.

[0014] According to a third aspect of the present invention, a tissue adhesive encapsulating stem cell microcapsules is provided for use in cell transplantation, cell regeneration, immune modulation, and tissue repair.

[0015] According to a fourth aspect of the present invention, a tissue adhesive containing stem cell microcapsules is provided for the treatment of osteoarthritis and chronic sinusitis.

[0016] Beneficial effects (1) The technical solution disclosed in this invention achieves precise preparation of stem cell-loaded microcapsules by combining microfluidic droplet technology with various natural polymer materials (including alginate, methacrylic acid-modified gelatin, and hyaluronic acid). The resulting microcapsules have a controllable particle size in the range of 10~800μm, a dispersion of less than 5%, and uniform morphology and stable structure. This preparation method can achieve droplet size control by adjusting the channel size and the water-oil two-phase flow rate ratio, thus adapting to the application needs of different nasal mucosal sites. The prepared microcapsules have excellent biocompatibility, providing a good three-dimensional survival microenvironment for cells, supporting the long-term survival of stem cells in the capsule and maintaining paracrine activity, effectively improving the cell retention rate and therapeutic durability after local transplantation, and significantly enhancing the therapeutic effect of stem cells in nasal mucosal repair.

[0017] (2) In addition to encapsulating cells, the stem cell-loaded microcapsules of the present invention can also simultaneously load a variety of bioactive substances (such as anti-inflammatory factors, epidermal growth factors, and angiogenesis factors), achieving sustained release of active molecules and synergistic effects with cells, thereby creating a sustained immune regulation and tissue repair environment locally. The natural polymer components in the microcapsule material can mimic the extracellular matrix (ECM) structure, providing biochemical signaling cues for stem cells and regulating their immune regulation and regenerative capacity. Stem cells release cytokines, exosomes, and growth factors through paracrine action, which can inhibit chronic inflammatory responses of the nasal mucosa, reduce eosinophil infiltration, and promote angiogenesis and epithelial regeneration, thereby restoring the nasal mucosal barrier function and improving the inflammatory microenvironment of chronic sinusitis.

[0018] (3) This invention further combines stem cell-loaded microcapsules with a tissue adhesive that can be cured in situ to form a composite system with good tissue adhesion, injectability, and sustained-release properties. This tissue adhesive is composed of hydrophilic polymers such as polyethylene glycol, polyvinyl alcohol, chitosan, hyaluronic acid, and poloxamer. Through a cross-linking reaction, it forms a stable three-dimensional network structure with an adhesion strength of 20-200 kPa, enabling it to firmly adhere to the lesion surface in the moist nasal cavity environment. This system can be injected into the nasal cavity lesion area via a minimally invasive method to achieve local curing and fixation, significantly increasing the retention time of stem cells in the inflamed area and preventing loss due to secretion flushing.

[0019] (4) The tissue adhesive-encapsulated stem cell microcapsule system of the present invention exhibited significant anti-inflammatory and repairing effects in a chronic sinusitis model. By continuously releasing exosomes and cytokines secreted by stem cells, it promoted the polarization of M1 macrophages to M2 type, reduced the expression levels of pro-inflammatory factors (IL-4, IL-5, IL-13, etc.), promoted epithelial cell regeneration and ciliary recovery, and significantly alleviated tissue edema and glandular hyperplasia. Compared with traditional drug or naked cell therapy, this system not only prolongs the survival time of stem cells but also enhances their local immune regulation and regenerative functions, effectively reducing postoperative recurrence rates and improving the quality of nasal cavity function recovery.

[0020] In summary, this invention overcomes the problems of short-lasting drug efficacy, strong local irritation, and high recurrence rate in traditional treatments by constructing a stem cell-loaded microcapsule tissue adhesive composite system with tissue adhesion, injectability, and sustained-release properties. It achieves long-term survival and continuous effect of stem cells at nasal mucosal lesions, providing an efficient, safe, and transferable innovative treatment solution for chronic sinusitis and other chronic mucosal inflammatory diseases. Attached Figure Description

[0021] Figure 1 This is a physical image of the microfluidic chip carrying stem cell microcapsules as described in Embodiment 1 of the present invention; Figure 2 The image shown is an electron microscope image of the alginate-encapsulated stem cell microcapsules described in Example 1 of this invention. Figure 3 The image shown is an electron microscope image of the GleMA-loaded stem cell microcapsule described in Example 2 of this invention. Figure 4 Characterization of the adhesive properties of the tissue adhesive for encapsulating stem cell microcapsules as described in Example 3 of this invention; Figure 5 Characterization of the adhesive properties of the photocuring process of the tissue adhesive containing stem cell microcapsules described in Example 4 of this invention; Figure 6 To investigate the toxicity of the tissue adhesive material of the stem cell-carrying microcapsules described in Example 5 of this invention to the stem cells within the capsules; Figure 7 To evaluate the toxicity of the tissue adhesive material of the stem cell-carrying microcapsules described in Example 6 of this invention to cells; Figure 8 Evaluation of the ROS clearance performance of the tissue adhesive material of the stem cell-carrying microcapsules described in Example 7 of this invention on inflammatory macrophages; Figure 9 The image shows the performance of the tissue adhesive material of the stem cell-carrying microcapsules described in Example 8 of this invention on in vitro tissue adhesion. Figure 10The image shows the morphological characteristics of inflammatory macrophages against the tissue adhesive material of the stem cell-carrying microcapsules described in Example 9 of this invention. Figure 11 This study investigates the adhesion performance of the tissue adhesive material for the stem cell-carrying microcapsules described in Example 10 of the present invention to rabbit nasal mucosa tissue. Detailed Implementation

[0022] The present invention will be further described below with reference to specific embodiments, but these embodiments are not intended to limit the invention in any way. Unless otherwise specified, the experimental methods used in the following embodiments are conventional methods, and the materials and reagents used can be purchased from biological or chemical reagent companies.

[0023] Example 1 This embodiment provides a method for preparing a tissue adhesive for encapsulating stem cell microcapsules, comprising the following steps: Step 1, Preparation of alginate hydrogel prepolymer solution: Dissolve 20 mg of alginate-RGD powder (sodium alginate-RGD, purchased from Shenzhen Huano Biotechnology Co., Ltd.) in 0.75 ml of serum-free a-MEM medium, and add 0.25 ml of 200 mM EDTA-Ca to obtain the hydrogel prepolymer solution.

[0024] Step 2, Stem Cell Culture: Taking human umbilical cord mesenchymal stem cells (UCMSCs) culture as an example, the growth medium consists of α-MEM (α-minimum Eagle's medium) and 10% fetal bovine serum (FBS, Gibco). Culture conditions are 37℃, 95% relative humidity, and 5% CO2. The cell culture medium is changed every three days. Before use, the cells are washed with phosphate-buffered saline (PBS), placed in trypsin / EDTA solution for 3 minutes, and then resuspended in the culture medium. Human mesenchymal stem cells are passaged. When the cells reach a confluence of over 80%, they are washed with sterile PBS, and 1 mL of the alginate hydrogel prepolymer solution prepared in Step 1 (cell concentration 1×10⁻⁶) is added. 7 The alginate-loaded stem cell microcapsule prepolymer solution was obtained by (number per mL).

[0025] Step 3, Preparation of stem cell-loaded microcapsules: The alginate-loaded stem cell microcapsule prepolymer solution obtained in Step 2 was pumped in at a flow rate of 0.1 mL / h as the cell phase. The continuous phase (oil phase) consisted of HFE7100 fluorinated oil, 0.1 w / v% glacial acetic acid, and 0.5 w / v% triblock Krytox-PEG-Krytox surfactant, and was pumped in at a flow rate of 1 mL / h. The droplets generated from the chip gelled due to the release of calcium ions from EDTA-Ca triggered by the glacial acetic acid in the oil phase. The product output channel of the chip was connected to a T25 bottle via a 0.68 mm diameter PE tube. The solution in the T25 bottle consisted of 20 v / v% perfluorooctanoic acid (PFO) in HFE7100 fluorinated oil and a pure culture medium layer on top. After the microcapsule solution demulsified in the lower layer, it gradually distributed to the bottom layer of the upper aqueous phase. The aqueous phase was separated to obtain Alg stem cell-loaded microcapsules. A physical image of the microfluidic chip containing the stem cell microcapsules is shown below. Figure 1 As shown, the microscopic image of Alg microcapsules is as follows: Figure 2 As shown.

[0026] Step 4, Preparation of the tissue adhesive for loading stem cell microcapsules: The volume fraction of the polymer in the biological adhesive used is 10%. The polymer is methacrylic acid modified F127 and methacrylic acid modified PEG (mass ratio 1:1). The specific preparation process is as follows: The alginate (Alg) loaded stem cell microcapsules obtained in Step 2 are cultured in α-MEM complete medium for 12 h, and then centrifuged in a 15 mL centrifuge tube at 1000 rpm for 3 min. The supernatant is discarded, and 3 mL of 10% methacrylic acid modified F127 (mass ratio of methacrylic acid to F127 is 1:2, where F127 was purchased from Shenzhen Huano Biotechnology Co., Ltd.) and 3 mL of 10% methacrylic acid modified PEG (mass ratio of methacrylic acid to PEG is 1:2, where the molecular weight of PEG is 0.4 kDa) are added and mixed evenly. A tissue adhesive containing stem cell microcapsules was obtained after irradiation with 405nm ultraviolet light for 20s. The tissue adhesive had a transmittance of 70%, a tissue adhesion strength of 30kPa, and a volume swelling rate of 20%.

[0027] Example 2 This embodiment provides a method for preparing a tissue adhesive for encapsulating stem cell microcapsules, comprising the following steps: Step 1, Preparation of methacrylic acid modified gelatin hydrogel prepolymer solution: 80 mg of methacrylic acid modified gelatin (purchased from Shenzhen Huano Biotechnology Co., Ltd.) was dissolved in 1 ml of serum-free a-MEM medium at 37 °C, and 1.5 mg of LAP (lithium phenyl-2,4,6-trimethylbenzoylphosphonate) was added to obtain the hydrogel prepolymer solution.

[0028] Step 2, Stem Cell Culture: Taking human umbilical cord mesenchymal stem cells (UCMSCs) culture as an example, the growth medium consists of α-MEM (α-minimum Eagle's medium) and 10% fetal bovine serum (FBS, Gibco). Culture conditions are 37℃, 95% relative humidity, and 5% CO2. The cell culture medium is changed every three days. Before use, the cells are washed with phosphate-buffered saline (PBS), placed in trypsin / EDTA solution for 3 minutes, and then resuspended in the culture medium. Human mesenchymal stem cells are passaged. When the cells reach a confluence of over 80%, they are washed with sterile PBS, and the methacrylic acid-modified gelatin hydrogel prepolymer solution prepared in Step 1 (cell concentration 1×10⁻⁶) is added. 7 The gelatin-loaded stem cell microcapsule prepolymer solution modified with methacrylic acid (number / mL) was obtained.

[0029] Step 3, Preparation of stem cell-loaded microcapsules: The methacrylic acid-modified gelatin stem cell-loaded microcapsule prepolymer obtained in Step 2 was pumped in at a flow rate of 0.1 mL / h as the cell phase. The continuous phase (oil phase) consisted of HFE7100 fluorinated oil and 0.5 w / v% of triblock Krytox-PEG-Krytox surfactant, and was pumped in at a flow rate of 1 mL / h. Droplets generated from the chip were connected at the output channel through a 0.68 mm diameter PE tube and irradiated with ultraviolet light for 10 s (200 mw / cm²). 2 The microcapsule solution (365 nm) triggers gel formation and flows into flask T25. The solution in flask T25 consists of 20 v / v % perfluorooctanoic acid (PFO) in HFE7100 fluorinated oil and a supernatant of pure culture medium. After demulsification in the lower layer, the microcapsule solution gradually distributes to the bottom layer of the upper aqueous phase. The aqueous phase is then collected to obtain the Gel-MA stem cell-loaded microcapsules. Microscopic images of the Gel-MA microcapsules are shown below. Figure 3 As shown.

[0030] Step 4, Preparation of the tissue adhesive for encapsulating stem cell microcapsules: The volume fraction of the polymer in the biological adhesive used is 10%. The polymer is methacrylic acid-modified F127 and methacrylic acid-modified PEG (mass ratio 1:1). The specific preparation process is as follows: The methacrylic acid GelMA-loaded stem cell microcapsules obtained in Step 2 were cultured in α-MEM complete medium for 12 h, and centrifuged in a 15 mL centrifuge tube at 1000 rpm for 3 min. The supernatant was discarded, and 3 mL of 10% methacrylic acid-modified F127 (mass ratio of methacrylic acid to F127 is 1:2, where F127 was purchased from Shenzhen Huano Biotechnology Co., Ltd.) and 3 mL of 10% methacrylic acid-modified PEG (mass ratio of methacrylic acid to PEG is 1:2, where the molecular weight of PEG is 0.4 kDa) were added, followed by 9 mg of LAP (lithium phenyl-2,4,6-trimethylbenzoylphosphonate) and mixed thoroughly. A tissue adhesive containing stem cell microcapsules was obtained after irradiation with 405nm ultraviolet light for 20s. The tissue adhesive had a transmittance of 70%, a tissue adhesion strength of 30kPa, and a volume swelling rate of 20%.

[0031] Example 3 This embodiment provides a rheological measurement method for characterizing the viscosity of tissue adhesives: The elastic and viscous properties of the material were characterized using a rheometer (Malverm, Kinexus). The rheological properties of a 1 mL tissue adhesive sample containing stem cell microcapsules prepared in Example 1 were tested using an 8 mm parallel plate configuration. The scan time range was set to 5 minutes, and time-scan tests were performed at a frequency of 1 Hz and a temperature of 25°C. Time-scan tests were also performed within a frequency range where the strain was 1%. The time-scan tests were conducted at 25°C, and the G (storage modulus) and G" (loss modulus) values ​​were obtained. Figure 4 As shown.

[0032] Example 4 This embodiment provides a rheological measurement method for characterizing the photocurable adhesive properties of tissue adhesives: The elastic and viscous properties of the material were characterized using a rheometer (Malverm, Kinexus). The rheological properties of a 1 mL tissue adhesive sample containing stem cell microcapsules prepared in Example 1 were tested using an 8 mm parallel plate configuration. The time-scan test was conducted at a frequency of 1 Hz and a temperature of 25°C, with a scan time range of 5 minutes. UV light irradiation was applied for 120 s during the time-scan test within a frequency range with a strain of 1%. The time-scan test was performed at 25°C, and the G (storage modulus) and G" (loss modulus) values ​​were obtained. Figure 5 As shown.

[0033] Example 5.

[0034] The toxicity of the tissue binder material of the stem cell-loaded microcapsules to the stem cells within the capsules was determined using a live / dead cell staining method. The tissue adhesive containing stem cell microcapsules prepared in Example 1 was seeded into 12-well plates at a volume of 1 mL per well. After UV irradiation for 20 s, α-MEM complete medium was added for co-incubation with the cells. The α-MEM complete medium was changed every 3 days. On days 1, 3, and 7 of culture, the cells were incubated for 3 h with Calcein AM / PI detection working solution. The cell fluorescence staining effect was observed using a laser confocal microscope. Calcein AM labeled live cells with excitation and emission at 494 nm and 517 nm, respectively; PI labeled necrotic cell nuclei with excitation and emission at 535 nm and 617 nm, respectively. The results of cell live and dead cell staining are as follows: Figure 6 As shown.

[0035] Example 6 Cell toxicity evaluation of tissue adhesive materials for stem cell-loaded microcapsules: The toxicity of the tissue adhesive containing the stem cell-loaded microcapsules prepared in Example 1 to RAW264.7 cells was determined using the CCK-8 assay. RAW264.7 cells were seeded into 10 mL LDM complete medium containing 10% FBS, 1% penicillin-dextrose antibiotics, and 100 μg / mL LPS. The cells were incubated overnight at 37°C in a 5% CO2 incubator. When the cell density reached 75% or higher, the medium was discarded, and the cells were collected at a density of 1 x 10⁵ cells / cm² per well. 3 Cells were seeded at a density suitable for 12-well plates, with 3 mL of DMEM added to each well. After 12 hours of complete culture at 37°C and 5% CO2, Transwell chambers containing tissue adhesive for the stem cell-loaded microcapsules prepared in Example 1 were added to each well. After 1 and 3 days of co-culture, the chambers were removed, and 1 mL of DMEM containing 10% CCK-8 reagent was added to each well. After 3 hours of incubation at 37°C and 5% CO2, the CCK-8 working solution was pipetted out and transferred to 96-well plates at 100 μL per well. The absorbance of cells in each well was measured using a microplate reader. Parameter settings: Detection wavelength 450 nm. Cytotoxicity test results are as follows: Figure 7 As shown.

[0036] Example 7 Evaluation of the ROS clearance performance of tissue adhesive materials carrying stem cell microcapsules against inflammatory macrophages: The effect of the tissue binder material of the stem cell-loaded microcapsules prepared in Example 1 on the ROS expression level of inflammatory macrophages was determined by flow cytometry. RAW264.7 cells were cultured at 5 × 10⁶ cells per well. 4 Cells were seeded at a density of [number] cells per well in 12-well plates and incubated at 37°C with 5% CO2 for 12 h. The culture medium was then discarded, and fresh complete DMEM medium (AM / FP (Alg-MSCs / F127-PEG)) was added to the wells in the Ctrl group. 400 Complete culture medium containing 1 µg / mL LPS was added to each well and incubated for 12 h. For the experimental group, Transwell chambers containing the tissue adhesive for the stem cell microcapsules described in Example 1 were added to each well, followed by 3 mL of LDM-MEM complete culture medium, and incubated for 24 h. The supernatant and Transwell chambers were removed, the culture medium was discarded, and the cells were washed three times with PBS. 300 µL of DCFH-DA probe solution diluted 1000 times with PBS was added, and the cells were incubated for 20 min. After washing the cells three times with PBS, the cells were collected, and the DCFH-DA fluorescence signal was detected by flow cytometry. The results are as follows: Figure 8 As shown.

[0037] Example 8 Performance observation of tissue adhesive materials carrying stem cell microcapsules on in vitro tissue adhesion: Take an area of ​​approximately 16cm 2 A piece of pigskin was injected with approximately 1 mL of the tissue adhesive material (10%) for the stem cell-loaded microcapsules prepared in Example 1. After irradiation with a UV flashlight for 20 seconds, the tissue adhesive material for the stem cell-loaded microcapsules changed from a liquid state to a solid state. The curing and bonding results are as follows. Figure 9 As shown.

[0038] Example 9 Evaluation of the morphology reversal performance of the tissue adhesive material for stem cell-loaded microcapsules prepared in Example 1 on inflammatory macrophages: Optical microscopy was used to observe the AM / FP macrophage group within the well plate obtained in Example 7. It was found that the morphology of inflammatory M1 macrophages, co-incubated with the tissue adhesive carrying stem cell microcapsules, transformed into that of non-inflammatory M2 macrophages. Image results are shown below. Figure 10 As shown.

[0039] Example 10 Performance evaluation of tissue adhesive materials carrying stem cell microcapsules on rabbit nasal mucosa tissue: The tissue adhesive for the stem cell-loaded microcapsules prepared in Example 1 was injected into the rabbit nasal cavity in a syringe at a volume of 1 mL. After irradiation with a UV flashlight for 20 seconds, the adhesive changed from a liquid state to a solid state. The curing and bonding results are as follows. Figure 11As shown.

[0040] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention in any way. Any person skilled in the art can make many possible modifications, equivalent substitutions, or improvements to the present invention using the methods described above without departing from the scope of the present invention. Therefore, any simple modifications, equivalent substitutions, equivalent changes, and alterations made to the above embodiments based on the technical essence of the present invention, without departing from the scope of the present invention, shall still fall within the protection scope of the present invention.

Claims

1. A tissue adhesive for encapsulating stem cell microcapsules, characterized in that, The tissue adhesive is composed of stem cell-loaded microcapsule hydrogel and biological adhesive, with living stem cells encapsulated inside. The stem cells are selected from at least one of umbilical cord mesenchymal stem cells, bone marrow mesenchymal stem cells, adipose stem cells, embryonic stem cells, and induced pluripotent stem cells; The bioadhesive is composed of a hydrophilic polymer and a block polymer, wherein the mass ratio of the hydrophilic polymer to the block polymer is 1:5 to 5:

1. The tissue adhesive has a transmittance of 60-100%, a tissue adhesion strength of 20-200 kPa, and a volume swelling rate of less than 50%.

2. The tissue adhesive according to claim 1, characterized in that, The number of live cells in the stem cell-loaded microcapsule is 1 to 10; The microcapsules carrying stem cells have a particle size of 50-150µm and a particle size distribution dispersion coefficient of 0.01-20%.

3. The tissue adhesive according to claim 1, characterized in that, The hydrophilic polymer is selected from at least one of polyethylene glycol, polyvinyl alcohol, gelatin, hyaluronic acid, alginate, and chitosan; When the hydrophilic polymer is polyethylene glycol, the molecular weight is 0.2 kDa to 6 kDa, preferably a combination of two or more of 0.2 kDa, 2 kDa, 4 kDa and 6 kDa, wherein the mass ratio of polyethylene glycol with molecular weights of 0.2 kDa, 2 kDa, 4 kDa and 6 kDa is 0~10:0~10:0~10:0~10; When the hydrophilic polymer is polyvinyl alcohol, the molecular weight is 2 kDa~75 kDa; When the hydrophilic polymer is hyaluronic acid, alginate, or chitosan, the degree of functional gene modification is ≥50%; When the hydrophilic polymer is gelatin, the degree of functional gene modification is ≥60%; The block polymer is poloxamer; The poloxamer is selected from at least two combinations of F127, F108, F88, F68, and F87, wherein the mass ratio of F127, F108, F88, F68, and F87 is 0-10:0-10:0-10:0-10:0-10.

4. A method for preparing the tissue adhesive according to any one of claims 1 to 3, characterized in that, Includes the following steps: (1) Preparation of hydrogel prepolymer: Alginate was dissolved in culture medium, and a crosslinking initiator was added to carry out crosslinking reaction to obtain hydrogel prepolymer; (2) Stem cell culture: The stem cells are passaged and cultured until the cells grow to more than 80%. They are washed and the hydrogel prepolymer obtained in step (1) is added to obtain the stem cell microcapsule prepolymer solution. (3) Preparation of stem cell-loaded microcapsules: The stem cell-loaded microcapsule prepolymer obtained in step (2) is used to prepare microdroplets through a microfluidic chip, which initiates a gelation reaction, removes the aqueous phase, and obtains cell microcapsules. (4) Preparation of adhesive for carrying stem cell microcapsules: Mix the cell microcapsules obtained in step (3) with the biological adhesive, add a cross-linking initiator to carry out the cross-linking reaction, and obtain the adhesive for carrying stem cell microcapsules. The bioadhesive is composed of a hydrophilic polymer and a block polymer, wherein the volume percentage of the polymer is 5% to 80%.

5. The preparation method according to claim 4, characterized in that, In step (1), the salt in the alginate is a metal salt, selected from at least one of calcium, barium, strontium, magnesium, iron, zinc, aluminum, copper, nickel, and gallium; In steps (1) and (4), the crosslinking initiator is a coordination reaction initiator, namely a chelate formed by one of the following ions: calcium ion, barium ion, strontium ion, magnesium ion, iron ion, zinc ion, aluminum ion, copper ion, nickel ion, and gallium ion with ethylenediaminetetraacetic acid or aminotriacetic acid. The concentration of the crosslinking initiator is 10~1000mM, based on calcium content; The volume fraction of the polymer in the bio-adhesive described in step (4) is 20% to 60%.

6. The preparation method according to claim 4, characterized in that, In step (1), alginate is replaced with a modified polymer material; The polymer material is selected from at least one of hyaluronic acid, gelatin, chitosan, agarose, dextran, fibroin, agar, matrix gum, proteoglycan, glycoprotein, laminin, polyethylene glycol, polyethylene glycol derivatives, polyvinyl alcohol, polyethylene oxide, polyamino acids, polyacrylamide, and Pluronic. The modifier in the modified polymer material is selected from at least one of acrylate, methacrylate, allyl isocyanate, azide, and alkyne; When alginate is replaced by polymer materials, crosslinking initiators include photochemical initiators, temperature-mediated crosslinking agents, and enzymes; The photochemical initiator is selected from at least one of 2-hydroxy-4-(2-hydroxyethoxy)-2-methylphenylacetone, lithium phenyl-2,4,6-trimethylbenzoylphosphonate, azo initiator VA086, benzoin methyl ether, and eosin Y, preferably, the irradiation wavelength is 365~780nm and the irradiation time is 0.00001~600s; The temperature-mediated crosslinking agent is used at a temperature of 0~40℃; The enzyme is selected from one of superoxide dismutase, thrombin, and glutaminase.

7. The preparation method according to claim 4, characterized in that, In step (2), the stem cells are selected from at least one of umbilical cord mesenchymal stem cells, bone marrow mesenchymal stem cells, adipose stem cells, embryonic stem cells, and induced pluripotent stem cells. The cell concentration of the stem cell-carrying microcapsule prepolymer solution mentioned in step (2) is greater than or equal to 4*10⁻⁶. 6 per mL.

8. The preparation method according to claim 4, characterized in that, In step (3), the microfluidic chip is a single-channel or multi-channel microfluidic chip. The microfluidic chip has at least a two-phase liquid inlet, an emulsification channel, and an output channel. The two-phase liquid inlet includes an aqueous liquid inlet and an oil liquid inlet. The inner walls of the microchannels of the microfluidic chip are all hydrophobically treated. The process of preparing microdroplets in step (3) is as follows: using a micropump or microinjector, a monodisperse water / oil / water double emulsion, i.e., microdroplets, is formed in the corresponding microchannels of the microfluidic device for the aqueous phase solution and oil phase solution composed of multiple fluids. The flow rate of the aqueous solution is 10~500 μL / hr, preferably 20~100 μL / h; The flow rate of the oil phase solution is 500~3000μL / hr, preferably 800~1000μL / h; The flow rate ratio of the aqueous solution to the oil solution is 0.01 to 1, preferably 0.1 to 0.5; The aqueous solution is the prepolymer solution of the stem cell-carrying microcapsules described in step (2); The oil phase solution is a mixed solution of fluorinated surfactant and fluorinated oil.

9. The use of the tissue adhesive containing stem cell microcapsules as described in any one of claims 1 to 3 in cell transplantation, cell regeneration, immune regulation, and tissue repair.

10. The use of the tissue adhesive containing stem cell microcapsules as described in any one of claims 1 to 3 in the treatment of osteoarthritis and chronic sinusitis.